China Pharma Revenue, Profits - CPHI Quarterly Income Statement

Add to My Stocks
$0.33 $0 (0%) CPHI stock closing price Mar 23, 2018 (Closing)

CPHI stock valuation based on fundamental analysis involves checking and analyzing financial statements and not just the China Pharma stock price. An income statement is one of the three key financial statements furnished by a company, the other two being the balance sheet and the cashflow statement. The income statement is always for an accounting period, typically for a year or quarter, and affects the stock. In this case, the CPHI stock is bound to reflect the impact of the QOQ growth of 8.22%. The operating expenses as shown in the China Pharma profit and loss statement for 2017 Q3 total to $2.44M. This line item shows that the operating expenses has decreased compared with last year. Also check: China Pharma assets and China Pharma free cash flow.

View and download details of revenue and profits for China Pharma for latest & last 40 quarters.
show more
View Previous Quarters
View Next Quarters
Fiscal year is Jan - Dec2017 Q32017 Q22017 Q12016 Q42016 Q32016 Q22016 Q12015 Q42015 Q3
China Pharma Revenues or Net Sales
Cost Of Goods Sold (COGS)2.74M2.26M2.56M3.53M2.77M3.06M2.99M4.37M4.15M
China Pharma Gross Profit
Research & Development Expense---------
Selling General & Admin Expense2.44M2.75M1.49M4.75M1.79M2.6M1.86M-1.13M3.8M
Income Before Depreciation Depletion Amortization-2.05M-2.13M-0.8M-3.07M-1.54M-2.22M-1.32M1.05M-3.88M
Depreciation Depletion Amortization---------
Non Operating Income---------
Interest Expense---------
China Pharma Pretax Income
Provision for Income Taxes---------
Investment Gains Losses---------
Other Income---------
Income Before Extraordinaries & Disc Operations-2.2M-2.29M-0.97M-3.43M-1.75M-2.45M-1.55M--4.15M
Extraordinary Items & Discontinued Operations---------
China Pharma Profit/ Loss (Net Income)
Average Shares used to compute Diluted EPS43.58M43.58M43.58M42.83M43.75M43.58M38.82M41.63M43.58M
Average Shares used to compute Basic EPS43.58M43.58M43.58M42.83M43.75M43.58M38.82M41.63M43.58M
Income Before Nonrecurring Items-2.2M-2.29M-0.97M-3.43M-1.75M-2.45M-1.55M--4.15M
Income from Nonrecurring Items--------0.07M-
China Pharma Earnings Per Share Basic Net
China Pharma Earnings Per Share Diluted Net
EPS Diluted Before Nonrecurring Items-0.05-0.05-0.02-0.08-0.04-0.06-0.040.02-0.10
Preferred Dividends Acc Pd---------
Dividends Common0.00--------
Dividend Per Share Common0.
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Quarters
View Next Quarters

Click here to view our Mylan financial analysis

Before investing one should read a report on China Pharma stock analysis. It helps to look at the following income statement items:

  • Top line: The word topline comes from the fact that the first line of an income statement refers to sales numbers. If you check you will find that CPHI stock has a topline or revenue of $3.16M for 2017 Q3 as per this China Pharma revenue chart. Investors look for stocks with a growing top line.
  • Bottom line: The word bottom line comes because it is usually the last line of the income statement and refers to the actual profits after deducting all expenses from the revenues. CPHI stock had a healthy bottom line growth.

The income statement is also called the profit and loss statement. Apart from the CPHI income statement, one can check the China Pharma historical stock prices to check how the price has moved with time.

China Pharma Income Statement - Key Financial Ratios

PS Ratio (price sales ratio)
Dividend Yield